Back to News
Market Impact: 0.35
Indapta Therapeutics Announces Oral Presentation of Clinical Proof-of-Concept Data for IDP-023 Allogeneic g-NK Cell Therapy Plus Isatuximab in Heavily Pretreated Multiple Myeloma at 2026 Annual Meeting of Society for Immunotherapy of Cancer
Source: Business Wire
Healthcare & BiotechCompany Fundamentals
Indapta reported that its IDP-023 g-NK cell therapy plus isatuximab achieved a 45% response rate in patients with daratumumab-refractory multiple myeloma. The result was presented at SITC 2026; the article provides no sample size or further clinical details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
More News
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- Paraguay’s Santiago Pena under arrest, new president Pedro Alliana sworn in
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says
- OpenAI valued at $1.25 trillion, as rival Anthropic nears its IPO